![](https://investorshub.advfn.com/uicon/539856.png?cb=1492977216)
Monday, April 10, 2017 11:47:28 AM
ViaDerma's "products" are based on the Phillips/Keough patent-pending transdermal delivery system referenced in my stickie. They have no innovative transdermal system under their name(s).
The Annual Report should clearly convey the above information.
This upcoming approval is only a bonus on the fact that we have Viabecline hitting market very soon, "a rollout of its FDA registered drug, Viabecline topical antibiotic" "The Company expects sales for 2017 to be about 500,000 units" at $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers."
We also have Onychomycosis which "Onychomycosis Clinical Studies Show Significant Results" and other products coming! This company will be worth over $1 in a short time. We have products that rival OWCP and CNBX which all started the same way at or below .01.
"Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream."
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM